{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T04:28:08Z","timestamp":1790483288125,"version":"4.1.0"},"reference-count":52,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2016,7,1]],"date-time":"2016-07-01T00:00:00Z","timestamp":1467331200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,3,2]],"date-time":"2016-03-02T00:00:00Z","timestamp":1456876800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","journal-of-hepatology.eu","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Hepatology"],"published-print":{"date-parts":[[2016,7]]},"DOI":"10.1016\/j.jhep.2016.02.030","type":"journal-article","created":{"date-parts":[[2016,2,26]],"date-time":"2016-02-26T02:47:22Z","timestamp":1456454842000},"page":"26-32","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":27,"title":["Modelling the impact of deferring HCV treatment on liver-related complications in HIV coinfected men who have sex with men"],"prefix":"10.1016","volume":"65","author":[{"given":"Cindy","family":"Zahnd","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luisa","family":"Salazar-Vizcaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Fran\u00e7ois","family":"Dufour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beat","family":"M\u00fcllhaupt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilles","family":"Wandeler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger","family":"Kouyos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janne","family":"Estill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Bertisch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andri","family":"Rauch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivia","family":"Keiser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhep.2016.02.030_b0005","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1097\/QAD.0b013e32833a0918","article-title":"Factors associated with specific causes of death amongst HIV-positive individuals in the D:A:D Study","volume":"24","author":"Smith","year":"2010","journal-title":"Aids"},{"key":"10.1016\/j.jhep.2016.02.030_b0010","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1111\/j.1468-1293.2012.01051.x","article-title":"Decreasing mortality and changing patterns of causes of death in the Swiss HIV Cohort Study","volume":"14","author":"Weber","year":"2013","journal-title":"HIV Med"},{"key":"10.1016\/j.jhep.2016.02.030_b0015","unstructured":"CDC. HIV and viral hepatitis, [accessed on 02.02.2014] http:\/\/www.cdc.gov\/hiv\/pdf\/library_factsheets_HIV_and_viral_Hepatitis.pdf; 2014."},{"key":"10.1016\/j.jhep.2016.02.030_b0020","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/2046-4053-3-31","article-title":"Hepatitis C virus infection among HIV-positive men who have sex with men: protocol for a systematic review and meta-analysis","volume":"3","author":"Hagan","year":"2014","journal-title":"Syst Rev"},{"key":"10.1016\/j.jhep.2016.02.030_b0025","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1093\/cid\/cis694","article-title":"Hepatitis C virus infections in the swiss HIV cohort study: a rapidly evolving epidemic","volume":"55","author":"Wandeler","year":"2012","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jhep.2016.02.030_b0030","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1053\/j.gastro.2009.02.006","article-title":"Evidence of a large, international network of HCV transmission in HIV-positive men who have sex with men","volume":"136","author":"van de Laar","year":"2009","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2016.02.030_b0035","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1093\/cid\/cir854","article-title":"Liver fibrosis progression after acute hepatitis C virus infection in HIV-positive individuals","volume":"54","author":"Vogel","year":"2012","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jhep.2016.02.030_b0040","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1089\/apc.2008.0238","article-title":"Rapid development of advanced liver fibrosis after acquisition of hepatitis C infection during primary HIV infection","volume":"23","author":"Osinusi","year":"2009","journal-title":"AIDS Patient Care STDS"},{"key":"10.1016\/j.jhep.2016.02.030_b0045","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1093\/cid\/cis1206","article-title":"Rapid progression to decompensated cirrhosis, liver transplantation, and death in HIV-infected men after primary HCV infection","volume":"56","author":"Fierer","year":"2012","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jhep.2016.02.030_b0050","first-page":"55A","article-title":"Effects of Sustained Virological Response (SVR) on the risk of liver transplant, hepatocellular carcinoma, death and re-infection: meta-analysis of 129 studies in 23,309 patients with Hepatitis C infection","volume":"60","author":"Hill","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2016.02.030_b0055","doi-asserted-by":"crossref","first-page":"2584","DOI":"10.1001\/jama.2012.144878","article-title":"Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis","volume":"308","author":"van der Meer","year":"2012","journal-title":"JAMA"},{"key":"10.1016\/j.jhep.2016.02.030_b0060","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1111\/jvh.12180","article-title":"Changes in liver fibrosis in HIV\/HCV-coinfected patients following different outcomes with peginterferon plus ribavirin therapy","volume":"21","author":"Labarga","year":"2014","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.jhep.2016.02.030_b0065","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1002\/hep.24561","article-title":"Excess liver-related morbidity of chronic hepatitis C patients, who achieve a sustained viral response, and are discharged from care","volume":"54","author":"Innes","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2016.02.030_b0070","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1093\/cid\/cir071","article-title":"Evaluation of liver fibrosis: concordance analysis between noninvasive scores (APRI and FIB-4) evolution and predictors in a cohort of HIV-infected patients without hepatitis C and B infection","volume":"52","author":"Mendeni","year":"2011","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jhep.2016.02.030_b0075","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1111\/j.1468-1293.2008.00662.x","article-title":"Hazardous drinking is associated with an elevated aspartate aminotransferase to platelet ratio index in an urban HIV-infected clinical cohort","volume":"10","author":"Chaudhry","year":"2009","journal-title":"HIV Med"},{"key":"10.1016\/j.jhep.2016.02.030_b0080","doi-asserted-by":"crossref","first-page":"329","DOI":"10.3851\/IMP2909","article-title":"Liver fibrosis progression despite HCV cure with antiviral therapy in HIV-HCV-coinfected patients","volume":"20","author":"Labarga","year":"2014","journal-title":"Antivir Ther"},{"key":"10.1016\/j.jhep.2016.02.030_b0085","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1086\/527565","article-title":"Progression of fibrosis in HIV and hepatitis C virus-coinfected patients treated with interferon plus ribavirin-based therapy: analysis of risk factors","volume":"46","author":"Bani-Sadr","year":"2008","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jhep.2016.02.030_b0090","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1111\/liv.12082","article-title":"HCV therapy in HIV-infected patients","volume":"33","author":"Sulkowski","year":"2013","journal-title":"Liver Int"},{"key":"10.1016\/j.jhep.2016.02.030_b0095","doi-asserted-by":"crossref","first-page":"S26","DOI":"10.1093\/infdis\/jis764","article-title":"Current management of hepatitis C virus infection in patients with HIV co-infection","volume":"207","author":"Sulkowski","year":"2013","journal-title":"J Infect Dis"},{"key":"10.1016\/j.jhep.2016.02.030_b0100","doi-asserted-by":"crossref","first-page":"S355","DOI":"10.1016\/j.dld.2013.09.001","article-title":"Optimizing treatment in HIV\/HCV coinfection","volume":"45S5","author":"Puoti","year":"2013","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.jhep.2016.02.030_b0105","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1001\/jama.2014.7085","article-title":"Treatment of hepatitis C: a systematic review","volume":"312","author":"Kohli","year":"2014","journal-title":"JAMA"},{"key":"10.1016\/j.jhep.2016.02.030_b0110","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1111\/liv.12396","article-title":"Treating HCV in HIV 2013: on the cusp of change","volume":"34","author":"Martel-Laferriere","year":"2014","journal-title":"Liver Int"},{"key":"10.1016\/j.jhep.2016.02.030_b0115","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1186\/1741-7015-11-234","article-title":"Managing HIV\/hepatitis C co-infection in the era of direct acting antivirals","volume":"11","author":"Rockstroh","year":"2013","journal-title":"BMC Med"},{"key":"10.1016\/j.jhep.2016.02.030_b0120","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1093\/cid\/cit804","article-title":"Editorial commentary: Management of hepatitis C Virus in HIV-infected patients in the era of direct-acting antivirals","volume":"58","author":"Zeremski","year":"2014","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jhep.2016.02.030_b0125","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1093\/cid\/ciu012","article-title":"Minimum costs for producing hepatitis C direct-acting antivirals for use in large-scale treatment access programs in developing countries","volume":"58","author":"Hill","year":"2014","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jhep.2016.02.030_b0130","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.jhep.2015.03.025","article-title":"EASL recommendations on treatment of hepatitis C 2015","volume":"63","year":"2015","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2016.02.030_b0135","unstructured":"Anthem Health Insurance. [accessed the 23.01.2015 https:\/\/www.anthem.com\/provider\/noapplication\/f0\/s0\/t0\/pw_e210963.pdf?na=pharminfo; 2015."},{"key":"10.1016\/j.jhep.2016.02.030_b0140","unstructured":"Moradpour D, Rauch A, Fehr J, M\u00fcllhaupt B. Treatment of chronic hepatitis C- September 2014 Update. http:\/\/www.sginf.ch\/ssi\/images\/ssi\/news\/SASL-SSI_HepC_EOS_Sept2014.pdf; 2014."},{"key":"10.1016\/j.jhep.2016.02.030_b0145","unstructured":"NICE. Sofosbuvir for treating chronic hepatitis C. https:\/\/www.nice.org.uk\/guidance\/ta330; 2015."},{"key":"10.1016\/j.jhep.2016.02.030_b0150","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1097\/QAD.0000000000000878","article-title":"The HIV care cascade in Switzerland: reaching the UNAIDS\/WHO targets for patients diagnosed with HIV","volume":"29","author":"Kohler","year":"2015","journal-title":"AIDS"},{"key":"10.1016\/j.jhep.2016.02.030_b0155","unstructured":"Luisa Salazar Vizcaya NB, Thomas Gsponer. gems: Generalized multistate simulation model. CRAN, R archive: http:\/\/cranr-projectorg\/web\/packages\/gems\/indexhtml; 2014."},{"key":"10.1016\/j.jhep.2016.02.030_b0160","doi-asserted-by":"crossref","first-page":"1","DOI":"10.18637\/jss.v064.i10","article-title":"Gems: an R package for simulating from disease progression models","volume":"64","author":"Blaser","year":"2015","journal-title":"J Stat Software"},{"key":"10.1016\/j.jhep.2016.02.030_b0165","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1097\/QAD.0b013e32831940a3","article-title":"Delayed anti-HCV antibody response in HIV-positive men acutely infected with HCV","volume":"23","author":"Thomson","year":"2009","journal-title":"Aids"},{"key":"10.1016\/j.jhep.2016.02.030_b0170","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/S0140-6736(96)07642-8","article-title":"Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups","volume":"349","author":"Poynard","year":"1997","journal-title":"Lancet"},{"key":"10.1016\/j.jhep.2016.02.030_b0175","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/S1473-3099(13)70149-X","article-title":"Boceprevir versus placebo with pegylated interferon alfa-2b and ribavirin for treatment of hepatitis C virus genotype 1 in patients with HIV: a randomised, double-blind, controlled phase 2 trial","volume":"13","author":"Sulkowski","year":"2013","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.jhep.2016.02.030_b0180","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1093\/cid\/cis779","article-title":"Response to pegylated interferon plus ribavirin among HIV\/hepatitis C virus-coinfected patients with compensated liver cirrhosis","volume":"55","author":"Mira","year":"2012","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jhep.2016.02.030_b0185","doi-asserted-by":"crossref","first-page":"ofv026","DOI":"10.1093\/ofid\/ofv026","article-title":"Incident hepatitis C Virus infections in the swiss HIV cohort study: changes in treatment uptake and outcomes between 1991 and 2013","volume":"2","author":"Wandeler","year":"2015","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.jhep.2016.02.030_b0190","doi-asserted-by":"crossref","first-page":"2551","DOI":"10.1097\/QAD.0b013e32836381cc","article-title":"HCV reinfection incidence and treatment outcome among HIV-positive MSM in London","volume":"27","author":"Martin","year":"2013","journal-title":"Aids"},{"key":"10.1016\/j.jhep.2016.02.030_b0195","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.antiviral.2014.03.012","article-title":"Reversal, maintenance or progression: What happens to the liver after a virologic cure of hepatitis C?","volume":"107C","author":"Lee","year":"2014","journal-title":"Antiviral Res"},{"key":"10.1016\/j.jhep.2016.02.030_b0200","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1053\/j.gastro.2008.05.044","article-title":"Eradication of hepatitis C virus in patients successfully treated for chronic hepatitis C","volume":"135","author":"Maylin","year":"2008","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2016.02.030_b0205","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/j.jhep.2013.05.015","article-title":"Slow regression of liver fibrosis presumed by repeated biomarkers after virological cure in patients with chronic hepatitis C","volume":"59","author":"Poynard","year":"2013","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2016.02.030_b0210","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1111\/jvh.12108","article-title":"Regression of liver fibrosis is progressive after sustained virological response to HCV therapy in patients with hepatitis C and HIV coinfection","volume":"20","author":"Casado","year":"2013","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.jhep.2016.02.030_b0215","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1056\/NEJMoa1105243","article-title":"Prevention of HIV-1 infection with early antiretroviral therapy","volume":"365","author":"Cohen","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2016.02.030_b0220","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.jhep.2014.03.011","article-title":"Should we await IFN-free regimens to treat HCV genotype 1 treatment-naive patients? A cost-effectiveness analysis (ANRS 12188)","volume":"61","author":"Deuffic-Burban","year":"2014","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2016.02.030_b0225","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1002\/hep.27736","article-title":"Cost-effectiveness of hepatitis C treatment for patients in early stages of liver disease","volume":"61","author":"Leidner","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2016.02.030_b0230","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0117334","article-title":"Estimating the clinical and economic benefit associated with incremental improvements in sustained virologic response in chronic hepatitis C","volume":"10","author":"McEwan","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.jhep.2016.02.030_b0235","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1097\/QAD.0000000000000093","article-title":"The cost-effectiveness of improved hepatitis C virus therapies in HIV\/hepatitis C virus coinfected patients","volume":"28","author":"Linas","year":"2014","journal-title":"Aids"},{"key":"10.1016\/j.jhep.2016.02.030_b0240","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0126984","article-title":"Cost-effectiveness analysis of sofosbuvir compared to current standard treatment in Swiss patients with chronic hepatitis C","volume":"10","author":"Pfeil","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.jhep.2016.02.030_b0245","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1093\/cid\/civ220","article-title":"The cost-effectiveness, health benefits, and financial costs of new antiviral treatments for hepatitis C virus","volume":"61","author":"Rein","year":"2015","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jhep.2016.02.030_b0250","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1001\/jama.2014.12627","article-title":"Life expectancy in patients with chronic HCV infection and cirrhosis compared with a general population","volume":"312","author":"van der Meer","year":"2014","journal-title":"JAMA"},{"key":"10.1016\/j.jhep.2016.02.030_b0255","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0125214","article-title":"Modeling the health and economic burden of hepatitis C virus in Switzerland","volume":"10","author":"Mullhaupt","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.jhep.2016.02.030_b0260","doi-asserted-by":"crossref","first-page":"2589","DOI":"10.1111\/j.1572-0241.2007.01466.x","article-title":"FibroTest and FibroScan for the prediction of hepatitis C-related fibrosis: a systematic review of diagnostic test accuracy","volume":"102","author":"Shaheen","year":"2007","journal-title":"Am J Gastroenterol"}],"container-title":["Journal of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827816001641?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827816001641?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,11,16]],"date-time":"2022-11-16T11:22:35Z","timestamp":1668597755000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168827816001641"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7]]},"references-count":52,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,7]]}},"alternative-id":["S0168827816001641"],"URL":"https:\/\/doi.org\/10.1016\/j.jhep.2016.02.030","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.726177806.793515334","asserted-by":"object"}]},"ISSN":["0168-8278"],"issn-type":[{"value":"0168-8278","type":"print"}],"subject":[],"published":{"date-parts":[[2016,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Modelling the impact of deferring HCV treatment on liver-related complications in HIV coinfected men who have sex with men","name":"articletitle","label":"Article Title"},{"value":"Journal of Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhep.2016.02.030","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 European Association for the Study of the Liver. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}